Navigation Links
Breast Cancer Treatment Is Reduced to One Week
Date:1/29/2008

Chicago-Area Community Hospital to Offer New Clinical Study to Breast

Cancer Patients

EVERGREEN PARK, Ill., Jan. 29 /PRNewswire/ -- Little Company of Mary Hospital and Health Care Centers in Evergreen Park, Illinois, near Chicago (http://www.PursuingPainFreeCancer.org/breastcancer), has announced it will offer a new clinical study by Xoft using electronic brachytherapy for the treatment of early stage breast cancer. The study involves the delivery of a safer form of radiation to breast cancer patients that will reduce the average treatment time from seven weeks to just one week.

Axxent Electronic Brachytherapy System uses a small electronic, low-energy X-ray source that delivers controlled radiation treatment directly to the targeted area. It is similar to another known procedure called Mammosite, but uses a different type of radiation. The Electronic Brachytherapy System uses a balloon-like device, which is implanted at the targeted area. Twice a day for five days, the balloon is expanded and a miniature X-ray tube is inserted.

Little Company of Mary is the first community hospital in Illinois to offer the study, joining only nine other sites in the country that offer the treatment. "I am proud to bring this new technology to Little Company of Mary and offer the women in Chicago's Southwest community a new and safer form of radiation therapy for the treatment of breast cancer," said radiation oncologist Dr. Adam Dickler. Dr. Dickler was the study's principal investigator when it was first offered in Illinois prior to arriving at Little Company of Mary in October.

Dr. Dickler says the major benefit for patients is the largely reduced treatment time, which would help many women receive the treatment they need without having to undergo therapy for seven weeks. A key component that sets this therapy apart is that electronic br
'/>"/>

SOURCE Little Company of Mary Hospital and Health Care Centers
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
2. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
3. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
4. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
5. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
6. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
7. New Drug Combination is Able to Eradicate Breast Metastases in Mice
8. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
9. Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)
10. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
11. Anastrozole Confirmed Superior in Breast Cancer Prevention

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...e-FirstCall/ -- Biotel Inc. (OTC Bulletin Board: B... September 30, 2009 with net earnings of $128,000,...,000. This compares to net earnings of $328,000, ...000 for the first quarter of last year. ,, Comm...ent and CEO Steve Springrose said: "Biotel enjoyed...
(Date:11/20/2009)... BD (Becton, Dickinson an...letion of its acquisition of HandyLab, Inc., an An...manufactures molecular diagnostic assays and autom...b announced an exclusive agreement for BD to devel...Lab Jaguar(TM) platform, the first fully integrate...
(Date:11/19/2009)...wswire/ -- Warner Chilcott plc (Nasdaq: WCRX ) to...ced secondary offering of 20,000,000 of its ordina...hare. The selling shareholders include funds affi...nking, J.P. Morgan Partners (advised by CCMP Capit...r institutional investors and members of the Compa...
Breaking Medicine Technology:Biotel Announced Profitable First Quarter Ended September 30, 2009 2BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4Ikaria 28R 29 Names New Chairman 14523 1Ikaria 28R 29 Names New Chairman 14523 2Hologic Expands Healthcare Investment in Asia 5563 1Hologic Expands Healthcare Investment in Asia 5563 2Hologic Expands Healthcare Investment in Asia 5563 3Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 1Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 2Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 3Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 4Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 5Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 6Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 7
... groups set out to confirm potential benefits of a...th breast cancer, PARIS, May 27 A new internatio...er is open for enrollment. The pivotal BETH,(BEvac...sitive Breast,Cancer) study is a Phase III clinica...s of combining two monoclonal antibodies, the anti...
...on A/S Today Announces That it has Entered Into a ...ity of Texas M. D., Anderson Cancer Center to De... Cancer, VEDBAEK, Denmark...alue gene expression analysis products, today,anno...agreement with the,Kleberg Center for Molecular Ma...
Other Medicine Technology:First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer 2First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer 3First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer 4Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center 2Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center 3
(Date:11/21/2009)...ASHINGTON, Nov. 21 DNC ...after the Senate voted to begin full debate of hea...ttp://www.newscom.com/cgi-bin/prnh/20080519/DNCLOG...ic step on the road to enacting health insurance r...enators will now have an opportunity to debate the...
(Date:11/21/2009)... LONDON, November 21, 2009 /PRNewswire-FirstCall/ ...st Test Test Test Test Test Test Test Test Test,Te...st Test Test Test Test,Test Test Test Test Test Te...est More test More test More test More test More t...est More test More test More test More,test More t...
(Date:11/21/2009)... New Haven Dental Group merges their p...ranford, CT. , (PRWEB) No...prised of partners Dr. David Gibson, Dr. Dean Clou...has just merged their growing practice with that o...en Dr. Pickman decided he wanted to retire from de...
(Date:11/20/2009)..., WASHINGTON, Nov. 20 ...rged the Senate to make essential changes its heal...aw on abortion funding and conscience protection o...grants and include strong provisions for adequate ... health care bill an "enormous disappointment" tha...
(Date:11/20/2009)... ST. LOUIS, Nov. 20 Ce...hat it will present at the Bank of America Merrill... 2-3, 2009, at the Crowne Plaza Hotel Times Square...esday, December 2nd at 8:30 a.m. Eastern Time. Inv...ive, audio webcast of Centene,s presentation at: ...
Breaking Medicine News(10 mins):Health News:Democratic National Committee Chairman Tim Kaine's Statement on the Senate's Vote to Proceed to Full Floor Debate of Health Insurance Reform Legislation 2Health News:New Haven Dental Group Expands Their Vision 2Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2
...he dangers of sun exposure that are backed by rese...a person's risk of developing skin// cancer, Ameri...ublished in the Journal of the American Academy of...ercent increase since 1999. However, this percenta...
...alth (MOH) says that Singapore will soon conduct a...mic Readiness.// More than 1,000 personnel ... the Ministry of Education, the Civil Aviation Aut... The two-day emergency exercise endeavors to si...
...earchers, in collaboration with investigators at J...rial to test// a new vaccine against the West Nile...cause serious illness, is making its yearly appear...ille have tested positive for the virus. "Wh...
... memory begins to decline, executive function is t...ession from mild cognitive// impairment, a pre-Alz.... Ron Petersen, M.D., Ph.D., Mayo Clinic neu...omeone with mild cognitive impairment starts havin...
... admissions given to 23 students in a post-graduat...rrent academic year. // "The division bench ...eld that the college administration had not conduc... behalf of two students who had filed a case again...
... Roche are conducting talks to make the expensive ...able.// According to Health Minister Tony Abbo...the delay in rushing Herceptin on to the Pharmaceu...ossible deal for patients. So we are to some exten...
Other Medicine News:Health News:Age and Socioeconomic Factors Are Strongest Determinants of Sunburn 2Health News:Age and Socioeconomic Factors Are Strongest Determinants of Sunburn 3Health News:University Participating in West Nile Vaccine Trial 2Health News:Decline in Concentration, Decision-Making and Problem-Solving 2
...CellaVision DM96 is an Automated Digital Cell Morp...e-classification/characterization, display, storag...es. Up to 96 stained peripheral blood smears can b... 60 per hour depending on the tests requested. Usi...
Cystoscopy "T". Drape, Sterile
Urological Drape
... the Penilab IV and the Penilab V have an exceptio...tal studies. Model 1060 is similar to the Model 1... can one be added later. The Penilab V has a Dopp... of the accessories you'll need to get started. L...
Medicine Products: